References
- Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2−) advanced breast cancer in the United States. J Med Econ 2014;16:278-88
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 2012;366:520-9